• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cardiorenal risk reduction guidance in diabetes: can we reach consensus?

作者信息

Sattar Naveed, McMurray John Jv, Cheng Alice Yy

机构信息

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G12 8TA, UK.

Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, G12 8TA, UK.

出版信息

Lancet Diabetes Endocrinol. 2020 May;8(5):357-360. doi: 10.1016/S2213-8587(20)30062-0. Epub 2020 Mar 11.

DOI:10.1016/S2213-8587(20)30062-0
PMID:32171053
Abstract
摘要

相似文献

1
Cardiorenal risk reduction guidance in diabetes: can we reach consensus?糖尿病中心肾风险降低指南：我们能达成共识吗？
Lancet Diabetes Endocrinol. 2020 May;8(5):357-360. doi: 10.1016/S2213-8587(20)30062-0. Epub 2020 Mar 11.
2
Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.根据心肾风险选择胰高血糖素样肽-1受体激动剂或钠-葡萄糖协同转运蛋白2抑制剂。
Lancet Diabetes Endocrinol. 2020 Feb;8(2):97-99. doi: 10.1016/S2213-8587(19)30414-0. Epub 2019 Dec 13.
3
Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.糖尿病肾病：胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的肾脏保护作用
Nat Rev Nephrol. 2017 Dec;13(12):728-730. doi: 10.1038/nrneph.2017.140. Epub 2017 Oct 9.
4
Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.基于随机对照试验的系统评价和荟萃分析：相较于单独使用钠-葡萄糖共转运蛋白 2 抑制剂，胰高血糖素样肽-1 受体激动剂联合钠-葡萄糖共转运蛋白 2 抑制剂在血糖疗效和安全性方面的表现。
Diabetes Res Clin Pract. 2019 Dec;158:107927. doi: 10.1016/j.diabres.2019.107927. Epub 2019 Nov 13.
5
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
6
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？
Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.
7
Invited review. Series: Implications of the recent CVOTs in type 2 diabetes: Which patients for GLP-1RA or SGLT-2 inhibitor?特邀评论。专题：近期 2 型糖尿病心血管结局试验的启示：哪些患者适合 GLP-1RA 或 SGLT-2 抑制剂？
Diabetes Res Clin Pract. 2020 Apr;162:108112. doi: 10.1016/j.diabres.2020.108112. Epub 2020 Mar 18.
8
Research digest: pioneering an oral GLP-1 receptor agonist.研究摘要：开拓口服胰高血糖素样肽-1受体激动剂
Lancet Diabetes Endocrinol. 2019 Dec;7(12):897. doi: 10.1016/S2213-8587(19)30360-2. Epub 2019 Nov 6.
9
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管益处。
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28.
10
Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.糖尿病合并心血管疾病患者中 SGLT2-i 与 GLP1-RA 的合理选择策略。
Curr Cardiol Rep. 2019 Jul 27;21(9):100. doi: 10.1007/s11886-019-1197-6.

引用本文的文献

1
Therapy of Type 2 diabetes: more gliflozines and less metformin?2型糖尿病的治疗：更多的格列净类药物还是更少的二甲双胍？
Eur Heart J Suppl. 2023 Apr 21;25(Suppl B):B171-B176. doi: 10.1093/eurheartjsupp/suad098. eCollection 2023 Apr.
2
Challenges in the Prevention and Management of Diabetic Kidney Diseases.糖尿病肾病预防与管理中的挑战
Front Clin Diabetes Healthc. 2021 Aug 23;2:728320. doi: 10.3389/fcdhc.2021.728320. eCollection 2021.
3
Cardiovascular risk and lifetime benefit from preventive treatment in type 2 diabetes: A post hoc analysis of the CAPTURE study.
2 型糖尿病患者的心血管风险和预防治疗的终身获益：CAPTURE 研究的事后分析。
Diabetes Obes Metab. 2023 Feb;25(2):435-443. doi: 10.1111/dom.14887. Epub 2022 Oct 24.
4
Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.在2型糖尿病和高心血管风险患者中，在标准治疗基础上加用司美格鲁肽可避免新的或复发性重大心血管事件所获得的估计生命年数。
Diabetes Care. 2022 May 1;45(5):1211-1218. doi: 10.2337/dc21-1138.
5
The efficacy and safety of Yuxingcao eye drops in the treatment of COVID-19 conjunctivitis: A protocol for a systematic review.鱼腥草滴眼液治疗新型冠状病毒肺炎结膜炎的疗效和安全性：一项系统评价方案
Medicine (Baltimore). 2020 Dec 4;99(49):e23093. doi: 10.1097/MD.0000000000023093.
6
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.达格列净在DAPA-HF研究中基于背景降糖治疗的疗效
Diabetes Care. 2020 Nov;43(11):2878-2881. doi: 10.2337/dc20-1402. Epub 2020 Sep 2.
7
Network Pharmacology-Based Identification of the Mechanisms of Shen-Qi Compound Formula in Treating Diabetes Mellitus.基于网络药理学的参芪复方治疗糖尿病机制的研究
Evid Based Complement Alternat Med. 2020 Jun 4;2020:5798764. doi: 10.1155/2020/5798764. eCollection 2020.
8
Efficacy and safety of Chinese herbal medicine for Coronavirus disease 2019: A protocol for systematic review and meta-analysis.2019年冠状病毒病的中药疗效与安全性：系统评价与荟萃分析方案
Medicine (Baltimore). 2020 May 29;99(22):e20157. doi: 10.1097/MD.0000000000020157.